Partnership drives our growth.
Together with our partners, we bring complex generics, branded/505(b)(2) products, specialty brands and biosimilars to patients across North America, Europe and MENA, through co-development, licensing and acquisitions.
Faisal Darwazeh
VP of Group Business Development and Alliances
What do we do with partners to bring more medicines to patients around the world?
We start from the patient and we work backwards. Hikma has an established network of regulatory, commercial and manufacturing across North America, Europe and the MENA region.
A partner often brings a complex generic, an innovative drug, a device or technology, and we have the infrastructure to take it to markets where it can make a difference.
That might be through in-licensing, co-development or acquisitions. The structure follows what gets the medicine to the patient the fastest, not the other way round.
What kind of partnerships are we looking to build next across the MENA, North America, and Europe?
In MENA, we’re the partner of choice for companies that want to reach patients across the region in all technologies and therapeutic categories.
In North America, we’re focused on complex products and technologies across injectables, inhalers, nasals and orals that strengthen our leading position.
In Europe, we are focused on bolt-on opportunities that give us scale and access to new markets and technologies across the hospital and retail segments.
Behind all of it, we’re interested in innovation that fits our footprint: new formulations, new delivery formats and new therapeutic categories.
What can a partner expect when they work with us?
Speed, clarity and follow through. We tell you early where we stand, and we’re straightforward in negotiation.
Hikma is still a family-rooted, entrepreneurial company. You will deal with senior people who can make decisions quickly.
Once we sign, we execute. Our regulatory, manufacturing, and commercial teams are involved from the start.
We treat partnerships as long-term relationships. Some of our partnerships date back to the 1980s, since our founding, and are still going strong today.
Your partner in the MENA: One platform, 17 markets
Kareem Darwazah VP of Business Development & Alliance Management, MENA discusses how Hikma's on-the-ground presence and end-to-end capabilities give partners a single, trusted platform to bring innovative medicines and technologies across many therapeutic areas to patients, and to build lasting partnerships that grow over time.
Your partner for complex and specialty medicines in the US
Brett Bukvic, VP, Business Development and Pipeline Selection, explains how Hikma's end-to-end US expertise, continued investment in R&D and manufacturing, and a long record of successful launches help partners bring complex generics and specialty medicines, including injectables, semi solids, liquids, respiratory and nasal products, to market faster.